ANROAlto Neuroscience, Inc.

1. Aug 27, 2026On August 26, 2026 (the “Effective Date” ), the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”) promoted Nicholas C. Smith, the Company’s Chief Financial Officer and Chief Business Officer, to the position of President and Chief Financial Officer, effective immediately.Director or officer change · Form 8-K
2. Aug 12, 2026Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
3. Jul 14, 2026On July 13, 2026, Alto Neuroscience, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters set forth therein (collectively, the “Underwriters”), to issue and sell 3,776,436 shares of common stock of the …Material agreement entered · Form 8-K
4. Jul 13, 2026Cash, Cash Equivalents and Restricted Cash as of June 30, 2026 On July 13, 2026, Alto Neuroscience, Inc. (the “Company”) announced that, based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and restricted cash were approximately $244.2 million as of …Earnings release · Form 8-K
5. May 28, 2026Appointment of Andrew Miller, Ph.D. to the Board On May 27, 2026, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of …Director or officer change · Form 8-K
6. May 13, 2026Equity Plan Amendments As noted in.Director or officer change · Form 8-K
7. May 13, 2026Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
8. Apr 1, 2026Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements.Other event · press release
9. Mar 16, 2026Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights.Earnings release · press release
10. Mar 16, 2026Private Placement of Common Stock and Warrants On March 16, 2026, Alto Neuroscience, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a …Material agreement entered · Form 8-K
11. Nov 12, 2025Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights.Earnings release · press release
12. Oct 20, 2025Private Placement of Common Stock and Warrants On October 19, 2025, Alto Neuroscience, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.